Skip to Content

Join the 'Ortho Evra' group to help and get support from people like you.

Ortho Evra News (Page 4)

Related terms: Evra Patch

Mylan Launches Xulane - First Generic Ortho Evra Patch

Posted 18 Apr 2014 by Drugs.com

PITTSBURGH, April 16, 2014 /PRNewswire/ – Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Xulane (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day), the generic version of Janssen Pharmaceuticals Inc.'s Ortho Evra®* (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day). This product is ...

FDA Medwatch Alert: Qualitest Pharmaceuticals Oral Contraceptives: Recall - Packaging Error

Posted 16 Sep 2011 by Drugs.com

includes Cyclafem 7/7/7, Cyclafem 1/35, Emoquette, Gildess FE 1.5/30, Gildess FE 1/20, Orsythia, Previfem, Tri-Previfem ISSUE: Qualitest Pharmaceuticals issued a nationwide, retail-level recall of multiple lots of oral contraceptives because a packaging error may result in the daily regimen for these products being incorrect and could leave women without adequate contraception, and at risk for...

FDA Medwatch Alert: Ortho Evra Contraceptive Transdermal Patch

Posted 19 Jan 2008 by Drugs.com

[Posted 01/19/2008] FDA modified the prescribing information for the Ortho Evra Contraceptive Transdermal (Skin) Patch to include the results of a new epidemiology study that found that users of the birth control patch were at higher risk of developing serious blood clots, also known as venous thromboembolism (VTE), than women using birth control pills. VTE can lead to pulmonary embolism. The...

FDA Medwatch Alert: Ortho Evra (norelgestromin/ethinyl estradiol)

Posted 20 Sep 2006 by Drugs.com

[Posted 09/20/2006] Ortho-McNeil and FDA notified healthcare professionals and patients about revisions to the prescribing information to inform them of the results of two separate epidemiology studies that evaluated the risk of developing a serious blood clot in women using Ortho Evra compared to women using a different oral contraceptive. The first study found that the risk of non-fatal venous...

FDA Medwatch Alert: Ortho Evra (norelgestromin/ethinyl estradiol transdermal system)

Posted 14 Nov 2005 by Drugs.com

[Posted 11/14/2005] FDA notified healthcare professionals and patients of revisions to the label for Ortho Evra, a skin patch approved for birth control, that includes a bolded warning about higher exposure to estrogen for women using the weekly patch compared to taking a daily birth control pill containing 35 micrograms of estrogen. A woman on Ortho Evra may be exposed to approximately 60%...

FDA Medwatch Alert: Counterfeit contraceptive patches

Posted 6 Feb 2004 by Drugs.com

FDA and Johnson and Johnson Co. of Raritan, NJ are warning the public about an overseas internet site selling counterfeit contraceptive patches that contain no active ingredients.The counterfeit contraceptive patches were promoted as Ortho Evra transdermal patches, which are FDA approved, and made by Johnson and Johnson's Ortho-McNeil Pharmaceutical, Inc. subsidiary. These counterfeit patches...

Ask a Question

Further Information

Related Condition Support Groups

Contraception, Birth Control

Ortho Evra Patient Information at Drugs.com